Patients' Access to Treatments Act of 2012

Issues relating to implementation of the Patient Protection & Affordable Care Act (PL111-148) including implementation of health insurance reform measures in the comprehensive health reform to provide coverage of the uninsured and annual and lifetime benefit limits; Medicare's Sustainable Growth Rate (SGR) reimbursements for physicians; drug shortage related legislation including: H.R.2245-Preserving Access to Life-Saving Medications Act, H.R.3839-Drug Shortage Prevention Act, S.296-Preserving Access to Life-Saving Medications Act, S.3187-Food and Drug Administration Safety and Innovation Act and policy issues related to medical imaging and radiation therapy reimbursement policy and H.R.4209, The Patient Access to Treatment Act.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Prevention and Public Health Fund, Affordable Care Act, HR 4209 The Patient's Access to Treatment Act

Client expense: $13,445 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

H.R.1316, Stop Oxy Abuse Act of 2011: To limit the approval of any drug containing controlled-release oxycodone hydrochloride H.R. 1513, Great Ape Protection and Cost Savings Act of 2011: Provisions related to pre-clinical testing H.R. 2674, 340B Program Improvement Act: Provisions related to 340B H.R. 4132, FAST Act: Provisions related to accelerated approval and other FDA matters H.R. 4156, Expanding and Promoting Expertise in Rare Treatments Act of 2012: To strengthen the FDAs ability to seek advice from external experts regarding rare diseases H.R. 4209, Patients Access to Treatments Act: To limit cost-sharing requirements applicable to prescription drugs in a specialty drug tier H.R. 4274, To amend title IV of the Public Health Service Act and title V of the Federal Food, Drug, and Cosmetic Act to permanently extend the provisions of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act of 2003 H.R. 6288, Patient Choice Act: To permit provisional approval of fast track products H.R. 6342, Compassionate Freedom of Choice Act: Provisions related to access to investigational drugs or devices for terminally ill patients H.R. 6584, Verifying Authority and Legality In Drug Compounding Act: Provisions relating to drug compounding H.R. 6611, Patient Access to Drugs in Shortage Act of 2012: Promote public notification and provide incentives to reduce drug shortages S. 296, Preserving Access to Life-Saving Medications Act: Provisions related to prescription drug shortages S. 810, Great Ape Protection and Cost Savings Act of 2011: Provisions related to pre-clinical testing S. 1699, Prescription Drug Cost Reduction Act: Provisions related to 340B S. 2002, Online Pharmacy Safety Act: To improve the safety of Internet pharmacies S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act: Provisions related to accelerated approval and other FDA matters S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012: Provisions related to FDA regulation S.2281, Expanding and Promoting Expertise in Rare Treatments Act of 2012: To strengthen the FDAs ability to seek advice from external experts regarding rare diseases S. 3187, Food and Drug Administration Safety and Innovation Act: Provisions related to user fee reauthorization and FDA reform Implementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including PPACA; Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking Vaccine-related policy issues Comparative effectiveness policy issues General HHS and FDA related advocacy Biopharmaceutical innovation policy issues Pharmaceutical supply chain security issues

Client expense: $4,120,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office

H.R. 5, Protecting Access to Healthcare Act: Provisions related to Independent Payment Advisory Board (IPAB) H.R. 8, American Taxpayer Relief Act of 2012: Medicare and tax related provisions H.R. 452, Medicare Decisions Accountability Act of 2011: Provisions related to Independent Payment Advisory Board (IPAB) H.R. 999, Medicare Prescription Drug Savings and Choice Act of 2011: Provisions related to Part D issues H.R. 2190 Medicare Drug Savings Act of 2011: Provisions related to Part D issues H.R. 4209, Patients Access to Treatments Act of 2012: Provisions related to capping specialty tier drugs and no cost-sharing above the non-preferred brand tier S. 365, Budget Control Act of 2011: Deficit reduction issues related to Medicare/Medicaid S. 668, Health Care Bureaucrats Elimination Act: Provisions related to Independent Payment Advisory Board (IPAB) S. 1206, Medicare Prescription Drug Savings Act of 2011: Provisions related to Part D issues S. 1699, Prescription Drug Cost Reduction Act: Provisions related to Medicare Part B, 340B, least costly alternative, and other provisions Deficit reduction policy issues Medicaid Program, Covered Outpatient Drugs rulemaking Dual eligibles coordination policy issues Implementation issues relating to the Physician Payment Sunshine Act, including Medicare, Medicaid, Childrens Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests rulemaking

Client expense: $4,120,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office

Monitor implementation of the Patient Protection and Affordable Care Act. (P.L. 111-148) S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments. S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013. Draft, House Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 451, Healthcare Truth and Transparency Act of 2011. H.R. 5707, Medicare Physician Payment Innovation Act of 2012. H.R. 6352, Resident Physician Shortage Reduction and Graduate Medical Education Accountability and Transparency Act. H.R. 6482, To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings. H.R. 6562, Resident Physician Shortage Reduction Act of 2012. H.R. 8, American Taxpayer Relief Act of 2012. Monitor the implementation of the Continuing Appropriations Resolution, 2013. (P.L. 112-175) Monitor federal issues and legislation associated with health care policy.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to implementation of the Patient Protection & Affordable Care Act (PL111-148) including implementation of health insurance reform measures in the comprehensive health reform to provide coverage of the uninsured and annual and lifetime benefit limits; Medicare's Sustainable Growth Rate (SGR) reimbursements for physicians; drug shortage related legislation including: H.R.2245-Preserving Access to Life-Saving Medications Act, H.R.3839-Drug Shortage Prevention Act, S.296-Preserving Access to Life-Saving Medications Act, S.3187-Food and Drug Administration Safety and Innovation Act and policy issues related to medical imaging and radiation therapy reimbursement policy and H.R.4209, The Patient Access to Treatment Act.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

--H.R. 4209, Patients' Access to Treatments Act of 2012, support concept of legislation but urge legislation to also ban co-insurance. --H.R. 3266, Lifespan Respite Care Reauthorization Act, support all provisions.

Client expense: $86,362 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medication within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payments/co-insurance rate for non-preferred brand drugs; HR 1971/S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans; HR 6584 - legislation that would impose federal requirements on compounding pharmacies

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. Pub. Law No. 112-240, American Taxpayer Relief Act of 2012, primarily matters related to funding for the National Breast and Cervical Cancer Early Detection Program and the National Institutes of Health.

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

S. 775 & H.R. 1810: Tom Lantos Pulmonary Hypertension Research & Education Act Access to Disability Benefits for Patients w/Pulmonary Hypertension Pulmonary Hypertension Research activities at NIH Pulmonary Hypertension education & awareness activities at CDC H.R. 4209: Patient Access to Treatments Act

Client expense: Not reported · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)

340B Drug Pricing Program; Accelerated approval; Antibiotic incentives; Bioequivalence of locally acting drugs; Drug safety/supply chain integrity; Drug shortages; Essential health benefits; Medicaid coverage; Medicare coverage and reimbursement; Orphan Drug Act; Federal grants for drug development; and H.R. 4209, Patients Access to Treatments Act of 2012 (entire bill).

Client expense: $100,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

H.R. 5 Protecting Access to Healthcare Act; H.R. 2245 / S. 296 Preserving Access to Life-Saving Medications Act; H.R. 3839 Drug Shortage Prevention Act; H.R. 4209 Patients' Access to Treatments Act; H.R. 6352 Resident Physician Shortage Reduction and Graduate Medical Education Accountability and Transparency Act; H.R. 6482 To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health services; H.R. 6562 Resident Physician Shortage Reduction Act

Client expense: $120,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues relating to implementation of the Patient Protection & Affordable Care Act (PL111-148) including implementation of health insurance reform measures in the comprehensive health reform to provide coverage of the uninsured and annual and lifetime benefit limits; Medicare's Sustainable Growth Rate (SGR) reimbursements for physicians; drug shortage related legislation including: H.R.2245-Preserving Access to Life-Saving Medications Act, H.R.3839-Drug Shortage Prevention Act, S.296-Preserving Access to Life-Saving Medications Act, S.3187- Food and Drug Administration Safety and Innovation Act and policy issues related to medical imaging and radiation therapy reimbursement policy and H.R.4209, The Patient Access to Treatment Act.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitor implementation of the Patient Protection and Affordable Care Act. (P.L. 111-148) S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments. S. 2196, Congressional Health Care for Seniors Act of 2012. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012. S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013. Draft, House Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013. H.R. 5, Protecting Access to Healthcare Act. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 451, Healthcare Truth and Transparency Act of 2011. H.R. 5707, Medicare Physician Payment Innovation Act of 2012. H.R. 6142, Assuring Medicare Stability and Access for Seniors Act of 2012. H.R. 6352, Resident Physician Shortage Reduction and Graduate Medical Education Accountability and Transparency Act. H.R. 6482, To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings. H.R. 6562, Resident Physician Shortage Reduction Act of 2012. HJRes 117, Continuing Appropriations Resolution, 2013. (P.L. 112-175) Ryans Fy2013 Budget: A Path to Prosperity: A Blueprint for American Renewal Monitor federal issues and legislation associated with health care policy.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1845/ S 960 Medicare IVIG Access Act; HR 2672/ S 1423 Preserving Access to Orphan Drugs Act; HR 1919 Bleeding Disorders Screening, Awareness and Further Education Act; HR 4209 Patients' Access to Treatments Act of 2012; pharmaceutical distribution and supply chain security issues; introductory visits to member offices who represent districts where Grifols has a facility

Client expense: $350,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5, Protecting Access to Healthcare Act: Provisions related to Independent Payment Advisory Board (IPAB) H.R. 452, Medicare Decisions Accountability Act of 2011: Provisions related to Independent Payment Advisory Board (IPAB) H.R. 999, Medicare Prescription Drug Savings and Choice Act of 2011: Provisions related to Part D issues H.R. 2190 Medicare Drug Savings Act of 2011: Provisions related to Part D issues H.R. 4209, Patients Access to Treatments Act of 2012: Capping specialty tier drugs and no cost-sharing above the non-preferred brand tier S. 365, Budget Control Act of 2011: Deficit reduction issues related to Medicare/Medicaid S. 668, Health Care Bureaucrats Elimination Act: Provisions related to Independent Payment Advisory Board (IPAB) S. 1206, Medicare Prescription Drug Savings Act of 2011: Provisions related to Part D issues S. 1251, Medicare and Medicaid FAST Act: Provisions related to Part D issues. S. 1699, Prescription Drug Cost Reduction Act: Provisions related to Medicare Part B, 340B, least costly alternative, and other provisions Deficit reduction policy issues Medicaid Program, Covered Outpatient Drugs rulemaking Dual eligibles coordination policy issues Medicare, Medicaid, Childrens Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests rulemaking

Client expense: $4,140,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012

Client expense: $25,001 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

Client expense: $53,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Prevention and Public Health Fund, Affordable Care Act, HR 4209 The Patients' Access to Treatment Act

Client expense: $13,445 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

Increasing NIH appropriations for FY2013 and opposing NIH cuts called for by sequestration; Support federal medical malpractice liability reform (HR. 5); Support protections for neurology patients participating in clinical trial participant; Support for maintaining the Stark In-Office Ancillary Services Exception, Support for physician payment reform; Support HR 4209 for patient access to biologic drugs; Advocating for changes in bills to promote Graduate Medical Education, HR 6352 and HR 6352, to remove list of eligible specialties; Support for neurology's inclusion in pediatric loan repayment programs offered by the Affordable Care Act; Commenting on health information technology enabled quality measures

Client expense: $170,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

H.R. 1845 & S. 960: Medicare IVIG Access Act H.R. 1919: Bleeding Disorder Screening, Awareness & Further Education Act H.R. 2672 / S 1423: Preserving Access to Orphan Drugs Act Introductory/Educational meetings with Congressional offices H.R. 4209: Patients Access to Treatment Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

--H.R. 3497, MODDERN Cures Act of 2011, support pathway for drug innovation and companion diagnostic development. --H.R. 4209, Patients' Access to Treatments Act of 2012, support concept of legislation but urge legislation to also ban co-insurance. --H.R. 3266, Lifespan Respite Care Reauthorization Act, support all provisions.

Client expense: $80,282 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4209 - Patients' Access to Treatments Act.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4209 Patients' Access to Treatments Act; H.R. 5 Protecting Access to Healthcare Act; S. 296 / H.R. 2245 Preserving Access to Life-Saving Medications Act; S. 2069 / H.R. 3891 Spending Reductions through Innovations in Therapies Agenda Act; H.R. 3839 Drug Shortage Prevention Act; S. 2113 Transforming the Regulatory Environment to Accelerate Access to Treatments; S. 2516 Food and Drug Administration Safety and Innovation Act; H.R. 5849 Charity Care Tax Deduction for Physicians Act of 2012

Client expense: $90,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

--H.R. 3497, MODDERN Cures Act of 2011, support pathway for drug innovation and companion diagnostic development. --H.R. 4209, Patients' Access to Treatments Act of 2012, support concept of legislation but urge legislation to also ban co-insurance. --S. 3187, Prescription Drug User Fee Act (PDUFA) Reauthorization, support reauthorization of PDUFA and urge enhanced focus on patient benefit risk analysis. --H.R. 3266, Lifespan Respite Care Reauthorization Act, support all provisions. --S. 597, A bill to amend title XVIII of the Social Security Act to include neurologists as primary care physicians for purposes of incentive payments for primary care services under the Medicare program, support all provisions. --H.R. 2224, Improving Physician Access in Teaching Hospitals (PATH) Act, support all provisions.

Client expense: $80,694 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitor implementation of the Patient Protection and Affordable Care Act. (P.L. 111-148) S. 2069, Spending Reductions through Innovations in Therapies Agenda Act of 2012. H.R. 3891, Spending Reductions through Innovations in Therapies Agenda Act of 2012. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments. S. 2196, Congressional Health Care for Seniors Act of 2012. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012. S. 2516, Food and Drug Administration Safety and Innovation Act. S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013. Draft, House Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013. H.R. 5, Protecting Access to Healthcare Act. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5853, Gray Market Drug Reform and Transparency Act of 2012. H.R. 451, Healthcare Truth and Transparency Act of 2011. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 5651, Food and Drug Administration Reform Act of 2012. H.R. 5707, Medicare Physician Payment Innovation Act of 2012. H.R. 5849, Charity Care Tax Deduction for Physicians Act of 2012. Ryans Fy2013 Budget: A Path to Prosperity: A Blueprint for American Renewal Monitor federal issues and legislation associated with health care policy.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Increasing NIH appropriations for FY2013; Support federal medical malpractice liability reform (HR. 5); Support protections for neurology patients participating in clinical trial participant; Support for maintaining the Stark In-Office Ancillary Services Exception, Support physician payment reform; Support for Alzheimers Disease specific appropriations; Support HR 4209 for patient access to biologic drugs; Support Appropriations for Biomedical Advanced Research and Development Authority (BARDA); Support inclusion of migraine/posttraumatic headache as an eligible category within the Congressionally Directed Medical Research Program.

Client expense: $270,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE

HR 1845 / S 960 Medicare IVIG Access Act HR 2672 / S 1423 Preserving Access to Orphan Drugs Act HR 1919 Bleeding Disorders Screening Awareness and Further Education Act Introductory visits to member offices who represent districts where Grifols has a facility S.3187 Food and Drug Administration Safety and Innovation Act; Drug Shortages Reporting Provisions H.R.4209 Patients' Access to Treatments Act of 2012

Client expense: $350,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

FY2013 Appropriations (LHHS and DoD); HR4209-Access to Affordable Treatments; Specialty Tiers and out of pocket costs for medications; Congressional Lupus Caucus recruitment; National Lupus Patient Registry at CDC; Lupus research at NIAMS

Client expense: $8,300 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

HR 3613, The Part D Beneficiary Appeals Fairness Act, Prevention and Public Health Fund, Affordable Care Act, HR 4209 The Patients' Access to Treatments Act

Client expense: $134,727 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE

See attached addendum for General Lobbying Issue Area: HCR - Healthcare Successful Insurance Industry Implementation of Health Reforms: good faith compliance standard, reasonable regulatory implementation timeline for compliance with PL 111-148 Affordable Private Health Care: Health Insurance Excise Tax; Realistic Essential Health Benefits; Effective Individual Mandate; Healthcare Delivery System Reforms; Small Employer Tax Credits; BCBSA's proposal "Building Tomorrow's Healthcare System: The Pathway to High-Quality, Affordable Care in America" State-based regulation: State Oversight of Premium Increases; Properly designed state based health insurance exchanges to improve competition and maximize choice; federal exchanges; federal rate review; existing state regulatory functions; Selling Health Insurance across state lines: HR371 Health Care Choice Act of 2011; HR1213 "Repeal mandatory funding provided to States in the PPACA to Establish Benefit Exchanges"; HR5 "HEALTH Act of 2011" Medical Loss Ratios: MLR Broker Fee HR1206 Access to Professional Health Insurance Advisors Act of 2011; State Innovation Waivers; Quality improvement definition; Consistent reporting requirements for all insurers; Transition for smaller states and Plans; include benefits for individuals as well as populations Health Care Quality: Delivery System Incentives to Promote Better Care; Payment Reforms; Patient-centered Primary Care/Medical Home; Comparative Effectiveness Research; Evidence Based Care; Health Disparities; Wellness; Chronic Care Management Health Information Technology Standards; Health Information Privacy; Electronic Health Records; Administrative Simplification; ICD10 implementation; Data Sharing; Data Aggregation; Centralized All-Payer Database Insurance Market Reform; Individual Market Reform; Small Group Market Reform; Small Business Healthcare; Guaranteed Issue; Community Rating; Health Status Rating; Health Savings Accounts/Medical Savings Accounts; Individual Mandate; MEWAs Federal Employee Health Benefit Program (FEHBP) regarding proposals to allow additional types of carriers including regional PPOs to be included in the coverage options offered by OPM. Comprehensive Primary Care Initiative grant proposal from CMMI. HR4209 "Patient's Access to Treatments Act of 2012" HR3630 "Middle Class Tax Relief and Job Creation Act of 2012"

Client expense: $20,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

See attached addendum for General Lobbying Issue Area: HCR - Healthcare Successful Insurance Industry Implementation of Health Reforms: "good faith compliance standard", reasonable regulatory implementation timeline for compliance with PL 111-148. Affordable Private Health Care: Health Insurance Excise Tax; Realistic Essential Health Benefits; Effective Individual Mandate; Healthcare Delivery System Reforms; Small Employer Tax Credits; BCBSA's proposal, "Building Tomorrow's Healthcare System: The Pathway to High-Quality, Affordable Care in America". State-based regulation: State Oversight of Premium Increases; Properly designed state based insurance exchanges to improve competition and maximize choice; federal exchanges; federal rate review; existing state regulatory functions; "Selling Health Insurance across State Lines; HR371 "Health Care Choice Act of 2011; "HR1213 "Repeal mandatory funding provided to States in the PPACA to Establish Benefit Exchanges"; HR5 "HEALTH Act of 2011" Medical Loss Ratios: MLR Broker Fee HR1206 "Access ot Professional Health Insurance Advisors Act of 2011"; State Innovation Waivers; Quality improvement definition; Consistent reporting requirements for all insurers; Transistion for smaller states and Plans; include benefits for individuals as well as populations. Health Care Quality: Delivery System Incentives to Promote Better Care, Payment Reforms; Patient-centered Primary Care/Medical Home; Comparative Effectiveness Research; Evidence Based Care; Health Disparities; Wellness' Chronic Care Management. Health Information Technology Standards; Health Information Privacy; Electronic Health Records; Administrative Simplification, ICD10 implementation; Data Sharing; Data Aggregation; Centralized-All Payer Database. Insurance Market Reform; Individual Market Reform; Small Group Market Reform; Small Business Healthcare; Guaranteed Issue: Community Rating; Health Status Rating; Health Savings Accounts/Medical Savings Accounts; Individual Mandate; MEWS Federal Employee Health Benefit Probram (FEHBP) regarding proposals to allow additional types of carriers including regional PPOs to be included in the coverage options offered by OPM. Blue Health Intelligence grant proposal from CMMI HR4209 "Patient's Access to Treatments Act of 2012" HR2182 "Generating Antibiotic Incentives Now Act of 2011" HR3630 "Middle Class Tax Relief and Job Creation Act of 2012"

Client expense: $370,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5 Protecting Access to Healthcare Act; S. 296 / H.R. 2245 Preserving Access to Life Saving Medications Act of 2011; H.R. 3839 Drug Shortage Prevention Act of 2012; H.R. 4209 Patients' Access to Treatments Act of 2012; S. 668 Health Care Bureaucrats Elimination Act; S. 660 PATIENTS Act of 2011; S. 2069 / H.R. 3891 Spending Reductions through Innovations in Therapies Agenda Act of 2012

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

See attached addendum for General Lobbying Issue Area: HCR - Healthcare Successful Insurance Industry Implementation of Health Reforms: good faith compliance standard, reasonable regulatory implementation timeline for compliance with PL 111-148 Affordable Private Health Care: Health Insurance Excise Tax; Realistic Essential Health Benefits; Effective Individual Mandate; Healthcare Delivery System Reforms; Small Employer Tax Credits; BCBSA's proposal "Building Tomorrow's Healthcare System: The Pathway to High-Quality, Affordable Care in America" State-based regulation: State Oversight of Premium Increases; Properly designed state based health insurance exchanges to improve competition and maximize choice; federal exchanges; federal rate review; existing state regulatory functions; Selling Health Insurance across state lines: HR371 Health Care Choice Act of 2011; HR1213 "Repeal mandatory funding provided to States in the PPACA to Establish Benefit Exchanges"; HR5 "HEALTH Act of 2011" Medical Loss Ratios: MLR Broker Fee HR1206 Access to Professional Health Insurance Advisors Act of 2011; State Innovation Waivers; Quality improvement definition; Consistent reporting requirements for all insurers; Transition for smaller states and Plans; include benefits for individuals as well as populations Health Care Quality: Delivery System Incentives to Promote Better Care; Payment Reforms; Patient-centered Primary Care/Medical Home; Comparative Effectiveness Research; Evidence Based Care; Health Disparities; Wellness; Chronic Care Management Health Information Technology Standards; Health Information Privacy; Electronic Health Records; Administrative Simplification; ICD10 implementation; Data Sharing; Data Aggregation; Centralized All-Payer Database Insurance Market Reform; Individual Market Reform; Small Group Market Reform; Small Business Healthcare; Guaranteed Issue; Community Rating; Health Status Rating; Health Savings Accounts/Medical Savings Accounts; Individual Mandate; MEWAs Federal Employee Health Benefit Program (FEHBP) regarding proposals to allow additional types of carriers including regional PPOs to be included in the coverage options offered by OPM. Blue Health Intelligence grant proposal from CMMI. HR4209 "Patient's Access to Treatments Act of 2012" HR2182 "Generating Antibiotic Incentives Now Act of 2011" HR3630 "Middle Class Tax Relief and Job Creation Act of 2012"

Client expense: $1,940,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

See attached addendum for General Lobbying Issue Area: HCR - Healthcare Successful Insurance Industry Implementation of Health Reforms: good faith compliance standard, reasonable regulatory implementation timeline for compliance with PL 111-148 Affordable Private Health Care: Health Insurance Excise Tax; Realistic Essential Health Benefits; Effective Individual Mandate; Healthcare Delivery System Reforms; Small Employer Tax Credits; BCBSA's proposal "Building Tomorrow's Healthcare System: The Pathway to High-Quality, Affordable Care in America" State-based regulation: State Oversight of Premium Increases; Properly designed state based health insurance exchanges to improve competition and maximize choice; federal exchanges; federal rate review; existing state regulatory functions; Selling Health Insurance across state lines: HR371 Health Care Choice Act of 2011; HR1213 "Repeal mandatory funding provided to States in the PPACA to Establish Benefit Exchanges"; HR5 "HEALTH Act of 2011" Medical Loss Ratios: MLR Broker Fee HR1206 Access to Professional Health Insurance Advisors Act of 2011; State Innovation Waivers; Quality improvement definition; Consistent reporting requirements for all insurers; Transition for smaller states and Plans; include benefits for individuals as well as populations Health Care Quality: Delivery System Incentives to Promote Better Care; Payment Reforms; Patient-centered Primary Care/Medical Home; Comparative Effectiveness Research; Evidence Based Care; Health Disparities; Wellness; Chronic Care Management Health Information Technology Standards; Health Information Privacy; Electronic Health Records; Administrative Simplification; ICD10 implementation; Data Sharing; Data Aggregation; Centralized All-Payer Database Insurance Market Reform; Individual Market Reform; Small Group Market Reform; Small Business Healthcare; Guaranteed Issue; Community Rating; Health Status Rating; Health Savings Accounts/Medical Savings Accounts; Individual Mandate; MEWAs Federal Employee Health Benefit Program (FEHBP) regarding proposals to allow additional types of carriers including regional PPOs to be included in the coverage options offered by OPM. Blue Health Intelligence grant proposal from CMMI. HR4209 "Patient's Access to Treatments Act of 2012"

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

See attached addendum for General Lobbying Issue Area: HCR - Healthcare Successful Insurance Industry Implementation of Health Reforms: good faith compliance standard, reasonable regulatory implementation timeline for compliance with PL 111-148 Affordable Private Health Care: Health Insurance Excise Tax; Realistic Essential Health Benefits; Effective Individual Mandate; Healthcare Delivery System Reforms; Small Employer Tax Credits; BCBSA's proposal "Building Tomorrow's Healthcare System: The Pathway to High-Quality, Affordable Care in America" State-based regulation: State Oversight of Premium Increases; Properly designed state based health insurance exchanges to improve competition and maximize choice; federal exchanges; federal rate review; existing state regulatory functions; Selling Health Insurance across state lines: HR371 Health Care Choice Act of 2011; HR1213 "Repeal mandatory funding provided to States in the PPACA to Establish Benefit Exchanges"; HR5 "HEALTH Act of 2011" Medical Loss Ratios: MLR Broker Fee HR1206 Access to Professional Health Insurance Advisors Act of 2011; State Innovation Waivers; Quality improvement definition; Consistent reporting requirements for all insurers; Transition for smaller states and Plans; include benefits for individuals as well as populations Health Care Quality: Delivery System Incentives to Promote Better Care; Payment Reforms; Patient-centered Primary Care/Medical Home; Comparative Effectiveness Research; Evidence Based Care; Health Disparities; Wellness; Chronic Care Management Health Information Technology Standards; Health Information Privacy; Electronic Health Records; Administrative Simplification; ICD10 implementation; Data Sharing; Data Aggregation; Centralized All-Payer Database Insurance Market Reform; Individual Market Reform; Small Group Market Reform; Small Business Healthcare; Guaranteed Issue; Community Rating; Health Status Rating; Health Savings Accounts/Medical Savings Accounts; Individual Mandate; MEWAs Federal Employee Health Benefit Program (FEHBP) regarding proposals to allow additional types of carriers including regional PPOs to be included in the coverage options offered by OPM. Blue Health Intelligence grant proposal from CMMI. HR4209 "Patient's Access to Treatments Act of 2012" HR2182 "Generating Antibiotic Incentives Now Act of 2011" HR3630 "Middle Class Tax Relief and Job Creation Act of 2012"

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

--H.R. 3497, MODDERN Cures Act of 2011, support pathway for drug innovation and companion diagnostic development. --H.R. 4209, Patients' Access to Treatments Act of 2012, support concept of legislation but urge legislation to also ban co-insurance. --Prescription Drug User Fee Act (PDUFA) Reauthorization, support reauthorization of PDUFA and urge enhanced focus on patient benefit risk analysis. --H.R. 3266, Lifespan Respite Care Reauthorization Act, support all provisions. --S. 597, A bill to amend title XVIII of the Social Security Act to include neurologists as primary care physicians for purposes of incentive payments for primary care services under the Medicare program, support all provisions. --H.R. 2224, Improving Physician Access in Teaching Hospitals (PATH) Act, support all provisions. --H.R. 1173, Fiscal Responsibility and Retirement Security Act of 2011, oppose repeal of Community Living Assistance Services and Supports (CLASS) Act and urge continued dialogue and development of viable solutions to address our nation's long-term care crisis.

Client expense: $159,069 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitor implementation of the Patient Protection and Affordable Care Act. (P.L. 111-148) S. 660, PATIENTS Act of 2011. S. 668, Health Care Bureaucrats Elimination Act. S. 1031, Medicaid Improvement and State Empowerment Act. H.R. 2013, Medicaid Improvement and State Empowerment Act. S. 2069, Spending Reductions through Innovations in Therapies Agenda Act of 2012. H.R. 3891, Spending Reductions through Innovations in Therapies Agenda Act of 2012. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments. S. 2196, Congressional Health Care for Seniors Act of 2012. H.R. 5, Protecting Access to Healthcare Act. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 1173, Fiscal Responsibility and Retirement Security Act of 2011. H.R. 3399, Medicare and Medicaid FAST Act. H.R. 3630, Temporary Payroll Tax Cut Continuation Act of 2011. (P.L. 112-96) H.R. 3839, Drug Shortage Prevention Act of 2012. H.R. 4209, Patients' Access to Treatments Act of 2012. Ryans Fy2013 Budget: A Path to Prosperity: A Blueprint for American Renewal Monitor federal issues and legislation associated with health care policy.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 3613, The Part D Beneficiary Appeals Fairness Act, Prevention and Public Health Fund, Affordable Care Act HR 4209 Patient Access to Treatment Act

Client expense: $133,393 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

Client expense: $190,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE